KBC Securities - Amoeba SA (AMEBA) Amoéba Announcing its first order from its partner Koppert

Report

KBC Securities

Guy Sips

Amoéba Announcing its first order from its partner Koppert

We welcome Amoéba announced its first order from its partner Koppert. As a result Amoéba delivered on its promise to become a commercial company. Recall that Amoéba's biocontrol activities are now structured around its subsidiary Green 4 Agro. Amoéba stressed that this first order is proof of the promising nature of its partnership with Koppert.

We reiterate our Buy rating and € 1.5 Target Price.

12/03/2026 1 EN

Underlying

Amoeba SA

Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.

See profile

FR0011051598 Euronext Paris France

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Guy Sips

Other Reports on these Companies

KBC Securities

Amoéba Transforming into an industrial and commercial company by end FY26

Amoéba stated that in FY25, major regulatory and commercial milestones have laid the groundwork for commercialisation in FY26. We maintain our positive stance (Buy, € 1.5 TP) as after FY25 marked by intense regulatory and pre-commercial activity (both in biocontrol and cosmetics, as well as recognition from agricultural and wine-growing professionals), FY26 could be a turning point for Amoéba, marking its transformation into an industrial and commercial company. This change is based on the latest regulatory advances, as the ANSES (French Agency for Food, Environmental and Occupational Health &...

February 24, 2026 February 24, 2026 1 EN

GlobeNewsWire

Gold medal winner at SIVAL, Amoéba displays its ambitions for its biocontrol solution

Gold medal winner at SIVAL, Amoéba displays its ambitions for its biocontrol solution Chassieu, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Chassieu (France), 20 January 2026 – 6:00 pm - Amoéba (FR0011051598 - ALMIB), industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, recaps its recent participation in SIVAL (International Exhibition of Plant Production Techniques) in Angers (France). During this leading European and global event for the crop industry, Amoéba won the gold medal in the SIVAL Innovation 2026 Competition...

January 20, 2026 January 20, 2026 1 EN

Morning Notes : AALB NA, OPTI BB, DSFIR NA, MELE BB, SHUR BB

: AALB NA, OPTI BB, DSFIR NA, MELE BB, SHUR BB

4h / 37m 4h / 37m 1 EN

Lynn Hautekeete

Lynn Hautekeete

Wereldhave Initiation note: Daily Life, Lifetime Returns

Over a 1-year period Wereldhave had a total return of 49.0%, a 34.3% outperformance vs. the EPRA index. The timing of this initiation comes after the stock already re-rated. We expect Wereldhave to outperform the midpoint of its FY26 guidance by 3.7% and see the premium to peers as justified given the growth rate. We initiate with an Accumulate rating and €23.0 TP.

5h / 12m 5h / 12m 1 EN

Wim Lewi

Wim Lewi

Shurgard Defending the moat weighs on short term profits

We believe that the cautious outlook at the results on 26/2 is related to new developments from the LNS acquisitions that are added to the All-Store income at low initial Occupancy and YoC%. Shurgard now expects the EPRA EPS growth to average between 6-8% over FY27-30 (10% KBCSe). Shurgard continues its UK expansion with the completion of 5 developments (LnS pipeline) and 1 from its original pipeline in FY26. These completions have an impact on its short term all-store metrics as new developments demand an aggressive pricing policy to get occupancy up. It can take up to 5-7 years to lift the ...

5h / 23m 5h / 23m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Amoéba Announcing its first order from its partner Koppert

We are a financial services provider for several types of professional clients, each with distinct needs.

Amoéba Transforming into an industrial and commercial company by end FY26

Gold medal winner at SIVAL, Amoéba displays its ambitions for its biocontrol solution

Morning Notes : AALB NA, OPTI BB, DSFIR NA, MELE BB, SHUR BB

Wereldhave Initiation note: Daily Life, Lifetime Returns

Shurgard Defending the moat weighs on short term profits

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe